Catalent Pharma Solutions, Inc.

Catalent Pharma Solutions, Inc. | Carbon3

Research summary

What the public record says about this company's decarbonization.

Cached 30 Oct 2026

Summary

AI-generated from public sources

Catalent has set SBTi-validated targets to cut absolute Scope 1 and 2 GHG emissions 42% by 2030 from a 2022 baseline on a 1.5°C pathway while requiring 70% of suppliers to adopt science-based targets by 2028, positioning the company against rising pharma-sector benchmarks for value-chain decarbonization. These goals will be advanced through targeted insetting actions including $25M renewable energy contracts with NextEra Energy and on-site solar, $18M low-carbon packaging co-development with Amcor and West, $15M electric/biofuel cold-chain logistics with DHL and Maersk, and $30M green-chemistry investments with BASF and Lonza, which together deliver 182,000 mtCO2e annual reductions and cover over 70% of energy use via ISO-certified systems. The initiatives convert sustainability from a cost center into an economic catalyst by generating $42M in projected ROI, $12M–$15M yearly cost savings and value from stabilized energy, reduced waste, and supplier discounts, plus access to $50M in green financing. Improved CDP, EcoVadis, and MSCI A ratings further strengthen reputation and regulatory resilience versus peers.

This report is generated by AI from public sources and may contain errors, so readers should check the linked sources before relying on it.

Sections in the report

5 sections

SBTi-Approved Climate Targets
Catalent has validated near-term targets with SBTi to reduce absolute Scope 1 and 2 GHG emissions by 42% by 2030 from a 2022 baseline, aligned with 1.5°C pathway, and to ensure 70% of supplier emissions have science-based targets by fiscal 2028.
Scope 1-3 Emissions Inventory and Reporting
Completed first full Scope 3 inventory and publishes annual emissions data (Scope 1, 2, 3) in Corporate Responsibility Report, including energy use, waste, and water metrics.
ISO-Certified Environmental Management
Implemented ISO-certified environmental management systems at 24 sites representing over 70% of total energy consumption.
ESG Ratings and Performance
Current ratings include CDP Climate C (improving), EcoVadis Silver (64), MSCI A (up from BBB), and ISS Prime status.
Supplier Decarbonization and Engagement
Focus on engaging suppliers for SBTi-aligned targets covering purchased goods and logistics emissions.

Catalent Pharma Solutions, Inc.

How the reported footprint breaks down by scope and year.

How Catalent Pharma Solutions, Inc. compares with its industry peers on Scope 3.

A claimed profile keeps the figures accurate and shows the company’s projects.

Reported emissions by year

Scope 3 categories are not itemized yet

What the SBTi listing says about the company's targets.

Voluntary credits retired for this company on public registries.

Scope 3 position

Disclosure coverage

What the public record says about this company's decarbonization.

Summary

Sections in the report

Decarbonization projects that name the company as a partner.